Drug intelligence / Profile preview

FB-418

Development stage: Phase 1
Lead developer: 1ST Biotherapeutics
Modality: Small Molecules
Administration: Oral

Overview

FB-418 is a small molecule drug under development by 1st Biotherapeutics for the treatment of Parkinson’s disease and amyotrophic lateral sclerosis (ALS). It acts as a dual inhibitor of leucine-rich repeat kinase 2 (LRRK2) and c-Abl (ABL1) tyrosine kinase, targeting pathways involved in neuroinflammation and neurotoxicity. FB-418 is administered orally and is currently in Phase I clinical trials in South Korea for both Parkinson’s disease and ALS. The drug aims to provide disease-modifying effects by blocking critical inflammatory responses that contribute to neurodegeneration[1][2][4][5].

Targets

LRRK2 (Leucine-rich repeat serine/threonine-protein kinase 2)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)

Beyond the preview

Go deeper on FB-418.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FB-418.

Explore the full profile